TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26059205

Group type: EXPERIMENTAL
Intervention: PressureEasy® device for continuous control of P cuff for 24 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Routine care using a manometer for discontinuous control of P cuff every 4 hours for 24 hours
Number of subjects: 18
Study: 26059238

Group type: EXPERIMENTAL
Intervention: Neurally controlled pressure support (PSN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional pneumatically-controlled pressure support (PSP)
Number of subjects: 12
Study: 26059242

Group type: EXPERIMENTAL
Intervention: Bone marrow-derived mononuclear cells (BMDMCs) administered through bronchoscopy (2 × 10(7) cells)
Number of subjects: 5
Study: 26059523

Group type: EXPERIMENTAL
Intervention: Physiotherapy treatment
Number of subjects: 140
Study: 26059540

Group type: EXPERIMENTAL
Intervention: Cripto-1 knockout by the CRISPR-Cas9 system
Number of subjects: 0
Study: 26059603

Group type: EXPERIMENTAL
Intervention: Adapted echo time optimized PRESS sequence for (1) H-MRS
Number of subjects: 26
Study: 26059647

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Boosted Atazanavir (ATV)
Number of subjects: 33
Study: 26059839

Group type: EXPERIMENTAL
Intervention: Mood Disorders Questionnaire (MDQ) added to the Edinburgh Postnatal Depression Scale (EPDS)
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: MDQ with traditional scoring
Number of subjects: 1279

Group type: EXPERIMENTAL
Intervention: MDQ scored without the impairment criterion
Number of subjects: 1279
Study: 26059948

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg once daily
Number of subjects: 111
Study: 26059979

Group type: EXPERIMENTAL
Intervention: Biopsychosocial factors assessment
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: Multivariable regression model with stepwise selection
Number of subjects: 1293

Group type: EXPERIMENTAL
Intervention: Psychosocial stressors
Number of subjects: 1293
Study: 26060202

Group type: EXPERIMENTAL
Intervention: Presence of G3I
Number of subjects: 572
Study: 26060285

Group type: EXPERIMENTAL
Intervention: Tenofovir-exposed infants
Number of subjects: 143

Group type: COMPARATOR
Intervention: Tenofovir-unexposed infants
Number of subjects: 143
Study: 26060319

Group type: EXPERIMENTAL
Intervention: Bronchiectasis exacerbations
Number of subjects: 48

Group type: COMPARATOR
Intervention: Potentially pathogenic microorganism or P. aeruginosa isolation
Number of subjects: 48
Study: 26060513

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% applied topically to upper eyelid margins for six months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Vehicle applied topically to upper eyelid margins for six months
Number of subjects: 130
Study: 26061561

Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided needle-based confocal laser endomicroscopy
Number of subjects: 0
Study: 26061661

Group type: EXPERIMENTAL
Intervention: e-cigarettes
Number of subjects: 959

Group type: COMPARATOR
Intervention: tobacco smoking
Number of subjects: 959

Group type: COMPARATOR
Intervention: dual smoking
Number of subjects: 959
Study: 26062008

Group type: EXPERIMENTAL
Intervention: ACCU-CHEK(®) Aviva
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Contour(®) XT
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: GlucoCheck XL
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: GlucoMen(®) LX PLUS
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ISO 15197-distributed samples
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison methods (glucose oxidase and hexokinase)
Number of subjects: 200
Study: 26062135

Group type: EXPERIMENTAL
Intervention: Imaginal exposure for PTSD with dialectical behavior therapy
Number of subjects: 16
Study: 26062610

Group type: EXPERIMENTAL
Intervention: Maternal care in Thatta, Pakistan
Number of subjects: 10000
Study: 26062714

Group type: EXPERIMENTAL
Intervention: Maternal Newborn Health Registry (MNHR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Performance metrics of data quality monitoring
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control program of MNHR
Number of subjects: 0
Study: 26062823

Group type: EXPERIMENTAL
Intervention: Anaplastic lymphoma kinase (ALK) inhibitor (crizotinib/Xalkori®) and a multikinase VEGF inhibitor (pazopanib/Votrient®)
Number of subjects: 1
Study: 26062899

Group type: EXPERIMENTAL
Intervention: Community-based pregnancy registry study
Number of subjects: 282626

Group type: EXPERIMENTAL
Intervention: Factors associated with higher LTFU
Number of subjects: 282626
Study: 26062992

Group type: EXPERIMENTAL
Intervention: No formal education
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Primary education only
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Secondary education only
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Lack of antenatal care
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Caesarean section delivery
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Hemorrhage
Number of subjects: 277736

Group type: EXPERIMENTAL
Intervention: Hypertensive disorders
Number of subjects: 277736
Study: 26063065

Group type: EXPERIMENTAL
Intervention: 100 g tomato puree providing 0.4 mg β-carotene
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Combination of 25 SNPs in 12 genes
Number of subjects: 33
Study: 26063067

Group type: EXPERIMENTAL
Intervention: B vitamin-containing supplements
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Supplemental folic acid
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin B-12
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Supplemental vitamin B-6
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary folate
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary vitamin B-6
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary choline
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary sources of folate
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary sources of vitamin B-6
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Dietary sources of vitamin B-12
Number of subjects: 368
Study: 26063125

Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation for hospital deliveries (4.8%)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Preterm births
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Low birth weight (<2500g)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Maternal age > 35 and <20 years
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Male gender, multiple gestation, major congenital anomalies, breech presentation/transverse lie, and no antenatal care
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Overall population rate of evidence-based interventions
Number of subjects: 7
Study: 26063292

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 269614
Study: 26063291

Group type: EXPERIMENTAL
Intervention: Early initiation of breastfeeding
Number of subjects: 255495

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding at 42 days post-partum
Number of subjects: 255495

Group type: EXPERIMENTAL
Intervention: Factors associated with failure to initiate early breastfeeding
Number of subjects: 255495

Group type: EXPERIMENTAL
Intervention: Factors associated with failure to achieve exclusive breastfeeding at 42 days
Number of subjects: 255495
Study: 26063346

Group type: EXPERIMENTAL
Intervention: Modern contraceptive usage
Number of subjects: 36687

Group type: EXPERIMENTAL
Intervention: Long-acting reversible contraceptives (intrauterine devices)
Number of subjects: 36687

Group type: EXPERIMENTAL
Intervention: Interventions aimed at increasing effective contraceptive methods
Number of subjects: 36687
Study: 26063350

Group type: EXPERIMENTAL
Intervention: Adolescent mothers aged 15-19 years
Number of subjects: 269273

Group type: EXPERIMENTAL
Intervention: Adolescent mothers aged <15 years
Number of subjects: 269273

Group type: COMPARATOR
Intervention: Adults aged 20-24 years
Number of subjects: 269273
Study: 26063475

Group type: EXPERIMENTAL
Intervention: SSE training intervention
Number of subjects: 274
Study: 26063483

Group type: EXPERIMENTAL
Intervention: Antenatal care attendance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First trimester antenatal care initiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of antenatal care visits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetanus toxoid coverage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Syphilis screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anemia screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV testing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Birth preparation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventative and screening interventions coverage
Number of subjects: 0
Study: 26063633

Group type: EXPERIMENTAL
Intervention: Pazopanib as a single agent
Number of subjects: 44
Study: 26063768

Group type: EXPERIMENTAL
Intervention: High marine n-3 polyunsaturated fatty acid levels (≥7.95 weight percentage)
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: Upper quartile of marine n-3 polyunsaturated fatty acid levels
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: High levels of marine n-3 polyunsaturated fatty acids
Number of subjects: 1990

Group type: EXPERIMENTAL
Intervention: High levels of eicosapentaenoic acid (a type of marine n-3 polyunsaturated fatty acid)
Number of subjects: 1990

Group type: COMPARATOR
Intervention: Total or individual marine n-3 polyunsaturated fatty acid levels
Number of subjects: 1990
Study: 26063893

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Letrozole + Cyclophosphamide
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Letrozole + Cyclophosphamide + Sorafenib
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: RDA (RNA disruption assay)
Number of subjects: 85
Study: 26064113

Group type: EXPERIMENTAL
Intervention: 2-week continuous administration of a protein-based formula (1.2 g/kg of ideal body weight/day) by nasogastric tube
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: 2-week continuous administration of a protein-based formula
Number of subjects: 364
Study: 26064192

Group type: EXPERIMENTAL
Intervention: semagacestat (γ-secretase inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 26065566

Group type: EXPERIMENTAL
Intervention: Surgical treatment (adenotonsillectomy)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Dietary treatment
Number of subjects: 117

Group type: COMPARATOR
Intervention: No treatment (non-OSAS)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure treatment
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Age as a risk factor for residual OSAS in surgically treated children
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: RDI at T0 and increase in BMI as risk factors for persistent OSAS in dietary treatment
Number of subjects: 117
Study: 26065651

Group type: EXPERIMENTAL
Intervention: Nilotinib plus multiagent chemotherapy (vincristine, daunorubicin, prednisolone) during induction treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nilotinib maintenance after consolidation or allo-HCT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nilotinib plus multiagent chemotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Subjects that failed to achieve MR3 or MR5
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MRD statuses just before allo-HCT and at 3 months after allo-HCT
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nilotinib combined with high-dose cytotoxic drugs
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MRD status at early postremission time
Number of subjects: 90
Study: 26066077

Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC III
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously diagnosed patients in FC IV
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC I
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC III
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly diagnosed patients in FC IV
Number of subjects: 0
Study: 26066323

Group type: EXPERIMENTAL
Intervention: Shared Decision-Making Renal Supportive Care communication intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (retrospective cohort)
Number of subjects: 0
Study: 26066744

Group type: EXPERIMENTAL
Intervention: Healthy group
Number of subjects: 102

Group type: COMPARATOR
Intervention: Glaucoma group
Number of subjects: 102
Study: 26066765

Group type: EXPERIMENTAL
Intervention: Romiplostim treatment for up to 4 years
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Romiplostim treatment
Number of subjects: 407
Study: 26066791

Group type: EXPERIMENTAL
Intervention: Cueing innovations for pressure ulcer prevention
Number of subjects: 0
Study: 26067854

Group type: COMPARATOR
Intervention: CAD but no angina
Number of subjects: 4128

Group type: COMPARATOR
Intervention: CAD and angina
Number of subjects: 4128
Study: 26068100

Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine
Number of subjects: 540

Group type: COMPARATOR
Intervention: Control group (non-SAM children)
Number of subjects: 540
Study: 26068287

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26068543

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 6 months
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Detraining after 6 months of aerobic exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Correlation analysis post-detraining
Number of subjects: 12
Study: 26068862

Group type: EXPERIMENTAL
Intervention: Confirmed Cardiovascular Autonomic Neuropathy (CAN)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Early Cardiovascular Autonomic Neuropathy (CAN)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Factors associated with CAN
Number of subjects: 557
Study: 26068866

Group type: EXPERIMENTAL
Intervention: Islet transplantation alone (ITA)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Islet after kidney transplantation (IAK)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 44
Study: 26069234

Group type: COMPARATOR
Intervention: Circulating FABP4 in patients with ST-segment-elevation myocardial infarction (24.9 ng/mL)
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Elevated FABP4 in patients with ACS
Number of subjects: 820

Group type: EXPERIMENTAL
Intervention: Circulating FABP4
Number of subjects: 820

Group type: COMPARATOR
Intervention: Baseline FABP4 in asymptomatic individuals
Number of subjects: 820
Study: 26069305

Group type: EXPERIMENTAL
Intervention: (18)F-DCFBC PET
Number of subjects: 13

Group type: COMPARATOR
Intervention: MR imaging
Number of subjects: 13
Study: 26070003

Group type: EXPERIMENTAL
Intervention: Prescreening and screening process for fecal donors
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Stool testing
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Blood testing
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Screening interview
Number of subjects: 116
Study: 26070008

Group type: EXPERIMENTAL
Intervention: High-confidence NBI evaluation for adenoma in diminutive lesions
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: High-confidence characterization of diminutive polyps
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: NPV for adenoma in the rectosigmoid
Number of subjects: 284
Study: 26070531

Group type: EXPERIMENTAL
Intervention: EGFR-TKIs
Number of subjects: 4196

Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 4196
Study: 26070683

Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258), 500mg orally once daily for five consecutive days, followed by a 2-day rest every week
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Number of subjects: 40
Study: 26071031

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 6906
Study: 26071053

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment (rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) followed by two cycles of R (R-CHOP-14)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: R-CHOP treatment
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Expression of CD5
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Expression of FOXP1
Number of subjects: 123
Study: 26071091

Group type: EXPERIMENTAL
Intervention: Deep tissue electrical pain stimulation by needle electrodes in the right groin (rectus muscle, ilioinguinal/iliohypogastric nerve and perispermatic cord)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Deep tissue electrical pain stimulation
Number of subjects: 19
Study: 26071133

Group type: EXPERIMENTAL
Intervention: Psychological factors (anxiety)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Infectious gastroenteritis (IGE)
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: Th2 cytokine phenotype at time of infection
Number of subjects: 1379

Group type: EXPERIMENTAL
Intervention: B cell numbers
Number of subjects: 1379
Study: 26071191

Group type: EXPERIMENTAL
Intervention: Multiplex PCR (mPCR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional microbiology (cMD)
Number of subjects: 40
Study: 26071868

Group type: EXPERIMENTAL
Intervention: Vorinostat (200 mg/day to 1000 mg/day, days -8 to -3) + Gemcitabine (10 mg/m²/minute over 4.5 hours, days -8 and -3) + Busulfan (targeted 4000 μM-minute/day, days -8 to -5) + Melphalan (60 mg/m²/day, days -3 and -2) + Rituximab (375 mg/m², days +1 and +8 for CD20(+) tumors)
Number of subjects: 78
Study: 26072112

Group type: EXPERIMENTAL
Intervention: hFABP combined with NT-proBNP
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: hFABP (4th quartile)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: hFABP
Number of subjects: 401

Group type: COMPARATOR
Intervention: TnI
Number of subjects: 401
Study: 26072149

Group type: EXPERIMENTAL
Intervention: Daptomycin at 4 mg/kg/day
Number of subjects: 55
Study: 26072403

Group type: EXPERIMENTAL
Intervention: Inducible caspase 9 (iC9) system with AP1903
Number of subjects: 0
Study: 26072932

Group type: EXPERIMENTAL
Intervention: 5-Ling Granule (15-22.5 g/day)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Tiapride (200-400 mg/day)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 603
Study: 26073352

Group type: EXPERIMENTAL
Intervention: Alisertib oral solution (OS) 25 mg
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alisertib powder-in-capsule (PIC) 50 mg
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alisertib oral solution (OS)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Alisertib powder-in-capsule (PIC)
Number of subjects: 35
Study: 26073451

Group type: EXPERIMENTAL
Intervention: KRN23 (0.05, 0.10 ± 0.01, 0.28 ± 0.06, and 0.48 ± 0.16 mg/kg administered subcutaneously every 28 days)
Number of subjects: 28
Study: 26073658

Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative follow-up
Number of subjects: 0
Study: 26074476

Group type: EXPERIMENTAL
Intervention: CRSwNP
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: CRSsNP
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control
Number of subjects: 63
Study: 26074990

Group type: EXPERIMENTAL
Intervention: IQP-VV-102
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 26075081

Group type: EXPERIMENTAL
Intervention: 10 mg of phylloquinone three times per week
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo administration three times per week
Number of subjects: 0
Study: 26075389

Group type: EXPERIMENTAL
Intervention: Dysphoric group
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 82
Study: 26075496

Group type: EXPERIMENTAL
Intervention: Novel TNXB missense variant c.12174C>G (p.C4058W)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Previously described TNXA/TNXB chimeras
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Novel TNXB variant
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Normal tenascin-X protein expression in dermal fibroblasts
Number of subjects: 246
Study: 26076437

Group type: EXPERIMENTAL
Intervention: Oswestry Disability Index (ODI) score of 22 or less (favorable outcome group)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Total Pain Sensitivity Questionnaire (PSQ) score
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Total PSQ score
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: ODI score
Number of subjects: 157
Study: 26076696

Group type: EXPERIMENTAL
Intervention: H2 robotic exoskeleton for gait rehabilitation
Number of subjects: 3
Study: 26076936

Group type: EXPERIMENTAL
Intervention: Coronary revascularisation within 90 days of CCTA
Number of subjects: 23745

Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 23745

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG) in patients with severe CAD (≥70% stenosis)
Number of subjects: 23745

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) in patients with severe CAD (≥70% stenosis)
Number of subjects: 23745
Study: 26077240

Group type: EXPERIMENTAL
Intervention: Alisertib 50 mg twice a day for 7 days on 21-day cycles
Number of subjects: 37
Study: 26077415

Group type: EXPERIMENTAL
Intervention: Antihistamine premedication
Number of subjects: 1632

Group type: COMPARATOR
Intervention: No premedication
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Concomitant immunosuppressant or corticosteroids
Number of subjects: 1632

Group type: COMPARATOR
Intervention: Antihistamines, intravenous steroids, and acetaminophen as preventative premedication
Number of subjects: 1632